Compare Asana Inc. (ASAN) vs Viatris Inc (VTRS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Asana Inc. vs Viatris Inc — how do they compare? Asana Inc. trades at $7.36 (market cap $1.69B), while Viatris Inc trades at $16.36 (market cap $18.94B). The key difference: Viatris Inc is far larger — about 11.2× Asana Inc.'s market cap, and Viatris Inc pays a 2.95% dividend while Asana Inc. pays none. Which is the better fit depends on your goals.
| ASAN | VTRS | |
|---|---|---|
Market Cap | $1.69B | $18.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.35 | $17.39 |
52-Week Low | $5.46 | $8.74 |
Enterprise Value | $1.51B | $31.15B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $7.33, down 0.54% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $378M in 2022 to $724M in 2025, though net losses persist. Recent Q1 2027 earnings beat expectations at $0.10 per share, and strategic acquisitions like StackAI enhance AI capabilities. Analyst consensus is mixed with 42% buy ratings and a $9.86 price target, representing 35% upside from current levels.
The outlook balances growth potential against profitability challenges. Positive catalysts include FedRAMP authorization for government contracts and AI innovation, but risks stem from intense competition with Microsoft and decelerating revenue growth. Cash flow turned positive in 2025, yet negative margins and high valuation multiples require careful monitoring for sustained improvement.
Viatris (VTRS) trades at $16.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The stock has beaten EPS estimates for the last three quarters, though it reported a net loss of $3.51B in 2025. Revenue has declined from $16.3B in 2022 to $14.3B in 2025. Positive news includes FDA acceptance of a new drug application for fast-acting meloxicam and a Phase 3 study success for VR-205, targeting a Japanese NDA by end of 2026.
The outlook is mixed: analyst consensus is a $20 price target with a 'Hold' bias, but high debt and negative margins pose risks. Upside potential hinges on pipeline success and debt reduction, while competitive pressures and execution challenges remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
